2023

McDowell, K., Adamson, C., Jackson, C., Campbell, R., Welsh, P. , Petrie, M. C. , McMurray, J. J.V. , Jhund, P. and Herring, N. (2023) Neuropeptide Y is elevated in heart failure and is an independent predictor of outcomes. European Journal of Heart Failure, (doi: 10.1002/ejhf.3085) (PMID:37937329) (Early Online Publication)

Burger, P. M. et al. (2023) Personalized lifetime prediction of survival and treatment benefit in patients with heart failure with reduced ejection fraction: the LIFE-HF model. European Journal of Heart Failure, (doi: 10.1002/ejhf.3028) (Early Online Publication)

Yang, M. et al. (2023) Impact of comorbidities on health status measured using the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with reduced and preserved ejection fraction. European Journal of Heart Failure, (doi: 10.1002/ejhf.2962) (PMID:37401511) (Early Online Publication)

Curtain, J. P. et al. (2023) Prevalent and incident anemia in PARADIGM-HF and the effect of sacubitril/valsartan. JACC: Heart Failure, 11(7), pp. 749-759. (doi: 10.1016/j.jchf.2022.12.012) (PMID:37407154)

Yang, M. et al. (2023) Knowledge about self-efficacy and outcomes in patients with heart failure and reduced ejection fraction. European Journal of Heart Failure, (doi: 10.1002/ejhf.2944) (PMID:37369637) (Early Online Publication)

Field, R. J. , Adamson, C., Jhund, P. and Lewsey, J. (2023) Joint modelling of longitudinal processes and time-to-event outcomes in heart failure: systematic review and exemplar examining the relationship between serum digoxin levels and mortality. BMC Medical Research Methodology, 23, 94. (doi: 10.1186/s12874-023-01918-4) (PMID:37076796) (PMCID:PMC10114381)

Mooney, L., Jackson, C. E., Adamson, C., McConnachie, A. , Welsh, P. , Myles, R. C. , McMurray, J. J.V. , Jhund, P. S. , Petrie, M. C. and Lang, N. N. (2023) Adverse outcomes associated with interleukin-6 in patients recently hospitalized for heart failure with preserved ejection fraction. Circulation: Heart Failure, 16(4), e010051. (doi: 10.1161/CIRCHEARTFAILURE.122.010051) (PMID:36896709) (PMCID:PMC10101136)

Adamson, C. et al. (2023) IGFBP-7 and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HF. JACC: Heart Failure, 11(3), pp. 291-304. (doi: 10.1016/j.jchf.2022.09.004) (PMID:36592046)

Curtain, J. P. et al. (2023) Investigator-reported ventricular arrhythmias and mortality in heart failure with mildly reduced or preserved ejection fraction. European Heart Journal, 44(8), pp. 668-677. (doi: 10.1093/eurheartj/ehac801) (PMID:36632831)

2022

Adamson, C. et al. (2022) Dapagliflozin for heart failure according to body mass index: the DELIVER trial. European Heart Journal, 43(41), pp. 4406-4417. (doi: 10.1093/eurheartj/ehac481) (PMID:36029309) (PMCID:PMC9622300)

Adamson, C., Jhund, P. S. and McMurray, J. J.V. (2022) Reply to 'the 50 shades of bilirubin'. Letter regarding the article 'liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HF'. European Journal of Heart Failure, 24(11), pp. 2206-2207. (doi: 10.1002/ejhf.2683) (PMID:36097136)

Ford, T. J. et al. (2022) Coronary artery perforations: Glasgow Natural History Study of Covered Stent Coronary Interventions (GNOCCI) Study. Journal of the American Heart Association, 11(19), e024492. (doi: 10.1161/JAHA.121.024492) (PMID:36129052) (PMCID:PMC9673697)

Adamson, C. et al. (2022) Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HF. European Journal of Heart Failure, 24(10), pp. 1856-1868. (doi: 10.1002/ejhf.2649) (PMID:36054568) (PMCID:PMC9805158)

Adamson, C. et al. (2022) Initial decline ("dip") in estimated glomerular filtration rate following initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: insights from DAPA-HF. Circulation, 146(6), pp. 438-449. (doi: 10.1161/CIRCULATIONAHA.121.058910) (PMID:35442064) (PMCID:PMC9354593)

Butt, J. H., Adamson, C., Docherty, K. F. , Vaduganathan, M., Solomon, S. D., Anand, I. S., Zannad, F., Køber, L., Jhund, P. S. and McMurray, J. J.V. (2022) Eligibility for pharmacological therapies in heart failure with reduced ejection fraction: implications of the new CKD-EPI creatinine equation for estimating glomerular filtration rate. European Journal of Heart Failure, 24(5), pp. 861-866. (doi: 10.1002/ejhf.2460) (PMID:35199418)

Adamson, C. and Jhund, P. S. (2022) Bringing FIDELITY to the estimate of treatment effects of finerenone in chronic kidney disease due to type 2 diabetes. European Heart Journal, 43(6), pp. 485-487. (doi: 10.1093/eurheartj/ehab827) (PMID:34888636)

Mikhail, P. et al. (2022) Coronary perforation incidence, outcomes and temporal trends (COPIT): a systematic review and meta-analysis. Open Heart, 9, e002076. (doi: 10.1136/openhrt-2022-002076) (PMID:36270713) (PMCID:PMC9594565)

2021

Butt, J. H. et al. (2021) Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide: insights from the DAPA-HF trial. Circulation: Heart Failure, 14(12), e008837. (doi: 10.1161/CIRCHEARTFAILURE.121.008837) (PMID:34802253)

Adamson, C. et al. (2021) Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. European Journal of Heart Failure, 23(10), pp. 1662-1672. (doi: 10.1002/ejhf.2308) (PMID:34272791)

2019

Adamson, C., Rocchiccioli, P., Brogan, R., Berry, C. and Ford, T. J. (2019) Post-operative myocardial infarction following aortic root surgery with coronary reimplantation: a case series treated with percutaneous coronary intervention. European Heart Journal: Case Reports, 3(4), pp. 1-6. (doi: 10.1093/ehjcr/ytz181) (PMID:32123801) (PMCID:PMC7042144)

Articles

McDowell, K., Adamson, C., Jackson, C., Campbell, R., Welsh, P. , Petrie, M. C. , McMurray, J. J.V. , Jhund, P. and Herring, N. (2023) Neuropeptide Y is elevated in heart failure and is an independent predictor of outcomes. European Journal of Heart Failure, (doi: 10.1002/ejhf.3085) (PMID:37937329) (Early Online Publication)

Burger, P. M. et al. (2023) Personalized lifetime prediction of survival and treatment benefit in patients with heart failure with reduced ejection fraction: the LIFE-HF model. European Journal of Heart Failure, (doi: 10.1002/ejhf.3028) (Early Online Publication)

Yang, M. et al. (2023) Impact of comorbidities on health status measured using the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with reduced and preserved ejection fraction. European Journal of Heart Failure, (doi: 10.1002/ejhf.2962) (PMID:37401511) (Early Online Publication)

Curtain, J. P. et al. (2023) Prevalent and incident anemia in PARADIGM-HF and the effect of sacubitril/valsartan. JACC: Heart Failure, 11(7), pp. 749-759. (doi: 10.1016/j.jchf.2022.12.012) (PMID:37407154)

Yang, M. et al. (2023) Knowledge about self-efficacy and outcomes in patients with heart failure and reduced ejection fraction. European Journal of Heart Failure, (doi: 10.1002/ejhf.2944) (PMID:37369637) (Early Online Publication)

Field, R. J. , Adamson, C., Jhund, P. and Lewsey, J. (2023) Joint modelling of longitudinal processes and time-to-event outcomes in heart failure: systematic review and exemplar examining the relationship between serum digoxin levels and mortality. BMC Medical Research Methodology, 23, 94. (doi: 10.1186/s12874-023-01918-4) (PMID:37076796) (PMCID:PMC10114381)

Mooney, L., Jackson, C. E., Adamson, C., McConnachie, A. , Welsh, P. , Myles, R. C. , McMurray, J. J.V. , Jhund, P. S. , Petrie, M. C. and Lang, N. N. (2023) Adverse outcomes associated with interleukin-6 in patients recently hospitalized for heart failure with preserved ejection fraction. Circulation: Heart Failure, 16(4), e010051. (doi: 10.1161/CIRCHEARTFAILURE.122.010051) (PMID:36896709) (PMCID:PMC10101136)

Adamson, C. et al. (2023) IGFBP-7 and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HF. JACC: Heart Failure, 11(3), pp. 291-304. (doi: 10.1016/j.jchf.2022.09.004) (PMID:36592046)

Curtain, J. P. et al. (2023) Investigator-reported ventricular arrhythmias and mortality in heart failure with mildly reduced or preserved ejection fraction. European Heart Journal, 44(8), pp. 668-677. (doi: 10.1093/eurheartj/ehac801) (PMID:36632831)

Adamson, C. et al. (2022) Dapagliflozin for heart failure according to body mass index: the DELIVER trial. European Heart Journal, 43(41), pp. 4406-4417. (doi: 10.1093/eurheartj/ehac481) (PMID:36029309) (PMCID:PMC9622300)

Adamson, C., Jhund, P. S. and McMurray, J. J.V. (2022) Reply to 'the 50 shades of bilirubin'. Letter regarding the article 'liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HF'. European Journal of Heart Failure, 24(11), pp. 2206-2207. (doi: 10.1002/ejhf.2683) (PMID:36097136)

Ford, T. J. et al. (2022) Coronary artery perforations: Glasgow Natural History Study of Covered Stent Coronary Interventions (GNOCCI) Study. Journal of the American Heart Association, 11(19), e024492. (doi: 10.1161/JAHA.121.024492) (PMID:36129052) (PMCID:PMC9673697)

Adamson, C. et al. (2022) Liver tests and outcomes in heart failure with reduced ejection fraction: findings from DAPA-HF. European Journal of Heart Failure, 24(10), pp. 1856-1868. (doi: 10.1002/ejhf.2649) (PMID:36054568) (PMCID:PMC9805158)

Adamson, C. et al. (2022) Initial decline ("dip") in estimated glomerular filtration rate following initiation of dapagliflozin in patients with heart failure and reduced ejection fraction: insights from DAPA-HF. Circulation, 146(6), pp. 438-449. (doi: 10.1161/CIRCULATIONAHA.121.058910) (PMID:35442064) (PMCID:PMC9354593)

Butt, J. H., Adamson, C., Docherty, K. F. , Vaduganathan, M., Solomon, S. D., Anand, I. S., Zannad, F., Køber, L., Jhund, P. S. and McMurray, J. J.V. (2022) Eligibility for pharmacological therapies in heart failure with reduced ejection fraction: implications of the new CKD-EPI creatinine equation for estimating glomerular filtration rate. European Journal of Heart Failure, 24(5), pp. 861-866. (doi: 10.1002/ejhf.2460) (PMID:35199418)

Adamson, C. and Jhund, P. S. (2022) Bringing FIDELITY to the estimate of treatment effects of finerenone in chronic kidney disease due to type 2 diabetes. European Heart Journal, 43(6), pp. 485-487. (doi: 10.1093/eurheartj/ehab827) (PMID:34888636)

Mikhail, P. et al. (2022) Coronary perforation incidence, outcomes and temporal trends (COPIT): a systematic review and meta-analysis. Open Heart, 9, e002076. (doi: 10.1136/openhrt-2022-002076) (PMID:36270713) (PMCID:PMC9594565)

Butt, J. H. et al. (2021) Efficacy and safety of dapagliflozin in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide: insights from the DAPA-HF trial. Circulation: Heart Failure, 14(12), e008837. (doi: 10.1161/CIRCHEARTFAILURE.121.008837) (PMID:34802253)

Adamson, C. et al. (2021) Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. European Journal of Heart Failure, 23(10), pp. 1662-1672. (doi: 10.1002/ejhf.2308) (PMID:34272791)

Adamson, C., Rocchiccioli, P., Brogan, R., Berry, C. and Ford, T. J. (2019) Post-operative myocardial infarction following aortic root surgery with coronary reimplantation: a case series treated with percutaneous coronary intervention. European Heart Journal: Case Reports, 3(4), pp. 1-6. (doi: 10.1093/ehjcr/ytz181) (PMID:32123801) (PMCID:PMC7042144)